What happened
Yuhan disclosed a supply contract with BridgeBio Pharma, Inc., worth US$38.8M, about 2.56% of its recent annual revenue, running through Mar 2028.
For context, this single contract equals about 2.56% of the company's most recent annual revenue.
| Counterparty | BridgeBio Pharma, Inc. |
|---|---|
| Contract value | US$38.8M |
| vs. recent revenue | 2.56% |
| Through | Mar 2028 (from May 2026) |
| Filed | 2026-05-06, Supply contract signed |
| Source | DART rcept 20260506800401 → open original filing |
Source: DART. Information only, not investment advice.